1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC)-Market Insights, Epidemiology and Market Forecast to 2030

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC)-Market Insights, Epidemiology and Market Forecast to 2030

  • May 2020
  • 200 pages
  • ID: 5893092
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

‘Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC)-Market Insights, Epidemiology and Market Forecast—2030’ report delivers an in-depth understanding of the ALK NSCLC, historical and forecasted epidemiology as well as the ALK NSCLC market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.
The ALK NSCLC market report provides current treatment practices, emerging drugs, ALK NSCLC market share of the individual therapies, current and forecasted ALK NSCLC market size from 2017 to 2030 segmented by seven major markets. The Report also covers current ALK NSCLC treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.

Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan

Study Period: 2017–2030
Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC): Disease Understanding and Treatment Algorithm
Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Overview
Lung cancer mainly begins in the lungs, and it may spread to lymph nodes or other organs in the body, such as the brain. However, cancer from other organs may also spread to the lungs. When cancer cells spread from one organ to another, they are called metastases.
There are mainly two types of lung cancer small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC can be defined as any type of epithelial lung cancer other than SCLC. It is mainly subcategorized into adenocarcinomas, squamous cell carcinomas, large cell carcinomas and several other types that occur less frequently include adenosquamous carcinomas, and sarcomatoid carcinomas. In these subtypes adenocarcinoma accounts for highest number of cases, i.e., approximately 47% followed by Squamous Cell Carcinoma and Large Cell Carcinoma.
There are several genetic mutations identified to play a major role in the progression of this indication. Mutations in EGFR, KRAS, and ALK are mutually exclusive in patients with NSCLC, and the presence of one mutation instead of another can influence response to targeted therapy. Among those most common are EGFR, KRAS, ROS-1, BRAF, C-Met, PD-L1 expression and others. Amongst all the mutations ALK mutation accounted for approximately 4% of the total cases of NSCLC.
ALK-positive mutation was discovered in 2007. ALK-positive lung cancers harbor a gene rearrangement referred to as the EML4-ALK fusion gene, compose a subset of tumors for which medical treatment has expanded rapidly (along with survival) in the past few years.

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Diagnosis
An ALK mutation is diagnosed by molecular profiling of a sample of the tumor. It’s important in doing this testing that an adequate supply of tissue from either a lung biopsy or lung cancer surgery is obtained. Researchers are also looking at ways to determine if an ALK mutation is present before genetic testing is done, or could substitute for genetic testing.
Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Treatment
There are several treatment options available to treat this condition in the seven major markets. Typically, chemotherapy, targeted treatments, and immunotherapy—alone or in combination—are used to treat lung cancer. Besides, pharmacological treatment choices, surgery, and radiation are also frequently opted. When the patient is in the initial stages, the tumor is usually resectable. Most stage I and stage II NSCLC are treated with surgery to remove the tumor. To recommend a treatment option to a patient of NSCLC, several key factors are taken into consideration, such age of the patient, previous medical history, health status, and smoking history. Along with those, another essential factor to consider is the stage of cancer at the time of diagnosis. Staging is usually carried out twice: after clinical and radiological examinations; and after surgery, in the case of the surgically resected tumor. There are several therapies approved under this category, such as Alunbrig (Brigatinib), Zykadia (Ceritinib), Xalkori (Crizotinib), and Alectinib. Apart from this, Lorbrena (Lorlatinib) is another therapy available for the ALK-positive NSCLC patient pool.
Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Epidemiology
The ALK NSCLC epidemiology division provide the insights about historical and current ALK NSCLC patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings
The total incident cases of ALK NSCLC in the 7MM were found to be 22,197 in 2017 which is expected grow during the study period, i.e., 2017–2030.
The disease epidemiology covered in the report provides historical as well as forecasted ALK NSCLC epidemiology [segmented as Total Incidence of NSCLC Total Incident cases of NSCLC patients by Histology, Total Diagnosed cases of NSCLC patients by Stages, Total ALK-NSCLC cases, and Treated Patient Pool of ALK-NSCLC] scenario of ALK NSCLC in the 7MM covering United States, EU5 countries (Germany, France, Italy , Spain, and United Kingdom), and Japan from 2017 to 2030.
Country Wise- Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Epidemiology
Estimates show the highest Incident population of ALK NSCLC is in the United States. Furthermore, among the European 5 countries, the Germany had highest incident population of NSCLC.
Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Drug Chapters
Drug chapter segment of the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer report encloses the detailed analysis of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Marketed Drugs
Xalkori (Crizotinib): Pfizer
Xalkori (Crizotinib), an ALK inhibitor, was first-ever approved treatment for metastatic NSCLC by the US FDA. This product received accelerated approval in 2011. The US FDA approval of Xalkori is based on data from 255 patients with locally advanced or metastatic ALK-positive NSCLC across two multicenter, single-arm studies, including a Phase II study (PROFILE 1005) and a Part 2 expansion cohort of a Phase I study (Study 1001).
Alunbrig (Brigatinib): Takeda
Alunbrig (Brigatinib) was approved by the US FDA in April 2017 for the treatment of patients with ALK+ metastatic NSCLC who have progressed on or are intolerant to Crizotinib. In the year 2018, the European Commission (EC) also granted marketing authorization for Alunbrig as a monotherapy for the treatment of adult patients with ALK+ NSCLC previously treated with Crizotinib. In April 2020, the European Commission (EC) extended the current marketing authorization of Alunbrig to include use as a monotherapy for the treatment of adult patients with ALK+ advanced NSCLC previously not treated with an ALK inhibitor. This decision came after a positive opinion from the CHMP on February 27, 2020.
Products detail in the report…

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Emerging Drugs
Ensartinib: Xcovery Holding Company
Xcovery is investigating their drug candidate, Ensartinib which is a potential best-in-class oral compound for the first-line treatment of ALK–positive NSCLC. This product has additional activity against MET, ABL, Axl, EPHA2, LTK, ROS1, and SLK. In phase I/II clinical trial, this product has shown promising activity in both ALK TKI naïve and crizotinib-resistant ALK+ NSCLC patients. Ensartinib is generally well tolerated with the most common toxicities being rash and nausea/vomiting, the latter often resolved with food.
At present, a global Phase III clinical trial (eXalt3) is ongoing comparing Ensartinib to Crizotinib in TKI naïve ALK-positive NSCLC patient. The primary purpose of this study is to evaluate the efficacy and safety of ensartinib vs. crizotinib in patients with ALK-positive NSCLC that have received up to one prior chemotherapy regimen and no prior ALK inhibitor.
Products detail in the report…

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Market Outlook

Key Findings
According to the analyst, Anaplastic lymphoma kinase Non-Small Cell Lung Cancer market in the 7MM is expected to change in the study period 2017–2030. The therapeutic market of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer in seven major markets was found to be USD 841 million in 2017 which is expected to increase during study period (2017–2030).

The United States Market Outlook
In 2017, the total market size of ALK NSCLC therapies was found to be USD 422 million in the United States which is expected to increase in the study period (2017–2030).

EU-5 Countries: Market Outlook
In 2017, the total market size of ALK NSCLC therapies was found to be USD 267 million in the EU-5 countries which is expected to increase in the study period (2017–2030).

Japan Market Outlook
The total market size of ALK NSCLC therapies in Japan was found to be USD 152 million in 2017.

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Pipeline Development Activities

The drugs which are in pipeline includes:
1. Ensartinib: Xcovery Holding Company: Phase III
Products detail in the report…

Pipeline Development Activities
Key Points
1. At present, a global Phase III clinical trial (eXalt3) is ongoing comparing Ensartinib to Crizotinib in TKI naïve ALK-positive NSCLC patient. The primary purpose of this study is to evaluate the efficacy and safety of ensartinib vs. crizotinib in patients with ALK-positive NSCLC that have received up to one prior chemotherapy regimen and no prior ALK inhibitor.

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Drugs Uptake
The current market is dominated by Alecensa (alectinib) which is expected to generate its peak revenue in coming years, and after that its revenue is expected to decline. This decline is a majorly attributed due to the presence of Lorbrena (because it is targeting the patient pool which is refractory to Crizotinib, Alectinib, and Ceritinib.
Access and Reimbursement Scenario in Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Therapies
• In 2018, Alecensa was recommended, within its marketing authorization, for untreated patients with NSCLC, whose tumors are identified as ALK-positive. Alecensa demonstrated considerable improvements in delaying cancer growth in enrolled patients. It has also shown significant improvements in preventing and delaying cancer spread into the brain.
• This decision was entirely based on data from the Phase III ALEX study, which showed a reduction in the risk of disease worsening, or death by 57% compared with standard of care Xalkori.
KOL- Views
To keep up with current market trends, we take KOLs and SME’s opinion working in Anaplastic lymphoma kinase Non-Small Cell Lung Cancer domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Anaplastic lymphoma kinase Non-Small Cell Lung Cancer market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Market by using various Competitive Intelligence tools that includes – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
• The report covers the descriptive overview of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer, explaining its causes, signs and symptoms, pathophysiology and currently available therapies.
• Comprehensive insight has been provided into the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer epidemiology and treatment in the 7MM.
• Additionally, an all-inclusive account of both the current and emerging therapies for Anaplastic lymphoma kinase Non-Small Cell Lung Cancer are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Anaplastic lymphoma kinase Non-Small Cell Lung Cancer market.

Report Highlights
• In the coming years, Anaplastic lymphoma kinase Non-Small Cell Lung Cancer market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Anaplastic lymphoma kinase Non-Small Cell Lung Cancer R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Major players are involved in developing therapies for Anaplastic lymphoma kinase Non-Small Cell Lung Cancer. Launch of emerging therapies, will significantly impact the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer market.
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Anaplastic lymphoma kinase Non-Small Cell Lung Cancer.
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Report Insights
• Patient Population
• Therapeutic Approaches
• Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Pipeline Analysis
• Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Report Key Strengths
• 11 Years Forecast
• 7MM Coverage

• Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market

• Drugs Uptake

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Report Assessment
• SWOT Analysis
• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Conjoint Analysis
• Market Attractiveness
• Market Drivers and Barriers

Key Questions

Market Insights:
• What was the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Market share (%) distribution in 2017 and how it would look like in 2030?
• What would be the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer total market Size as well as market size by therapies across the 7MM during the study period (2017–2030)?
• What are the key findings pertaining to the market across the 7MM and which country will have the largest Anaplastic lymphoma kinase Non-Small Cell Lung Cancer market size during the study period (2017–2030)?
• At what CAGR, the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer market is expected to grow in the 7MM during the study period (2017–2030)?
• What would be the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer market outlook across the 7MM during the study period (2017–2030)?
• What would be the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer market growth till 2030 and what will be the resultant market size in the year 2030?
• How would the market drivers, barriers and future opportunities affect the market dynamics and a subsequent analysis of the associated trends?
• Anaplastic lymphoma kinase Non-Small Cell Lung Cancer patient types/ pool where unmet need is more and whether emerging therapies will be able to address the residual unmet need?
• How emerging therapies are performing on the parameters like efficacy, safety, route of administration (RoA), treatment duration and frequencies based on their clinical trial results?
• Among the emerging therapies, what are the potential therapies which are expected to disrupt the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer market?

Epidemiology Insights:
• What is the disease risk, burden and unmet needs of the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer?
• What is the historical Anaplastic lymphoma kinase Non-Small Cell Lung Cancer patient pool in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
• What would be the forecasted patient pool of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer in 7 major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Anaplastic lymphoma kinase Non-Small Cell Lung Cancer?
• Out of all the 7MM countries, which country would have the highest Incident population of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer during the study period (2017–2030)?
• At what CAGR the population is expected to grow in the 7MM during the study period (2017–2030)?
• What are the various recent and upcoming events which are expected to improve the diagnosis of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
• What are the current options for the treatment of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer along with the approved therapy?
• What are the current treatment guidelines for the treatment of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer in the US, Europe and Japan?
• What are the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer?
• How many therapies are developed by each company for the treatment of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer?
• How many emerging therapies are in mid stage, and late stage of development for the treatment of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Anaplastic lymphoma kinase Non-Small Cell Lung Cancer and their status?
• What are the key designations that have been granted for the emerging therapies for Anaplastic lymphoma kinase Non-Small Cell Lung Cancer?
• What are the global historical and forecasted market of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer?

Reasons to buy
The report will help in developing business strategies by understanding trends shaping and driving the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer market.
To understand the future market competition in the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer market and Insightful review of the key market drivers and barriers.
Organize sales and marketing efforts by identifying the best opportunities for Anaplastic lymphoma kinase Non-Small Cell Lung Cancer in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.
Organize sales and marketing efforts by identifying the best opportunities for Anaplastic lymphoma kinase Non-Small Cell Lung Cancer market.
To understand the future market competition in the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer market.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2020

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on